507 related articles for article (PubMed ID: 24464041)
1. Tau promotes neurodegeneration through global chromatin relaxation.
Frost B; Hemberg M; Lewis J; Feany MB
Nat Neurosci; 2014 Mar; 17(3):357-66. PubMed ID: 24464041
[TBL] [Abstract][Full Text] [Related]
2. Targeted Downregulation of dMyc Suppresses Pathogenesis of Human Neuronal Tauopathies in Drosophila by Limiting Heterochromatin Relaxation and Tau Hyperphosphorylation.
Chanu SI; Sarkar S
Mol Neurobiol; 2017 May; 54(4):2706-2719. PubMed ID: 27000837
[TBL] [Abstract][Full Text] [Related]
3. Transgenic Drosophila models of Alzheimer's disease and tauopathies.
Iijima-Ando K; Iijima K
Brain Struct Funct; 2010 Mar; 214(2-3):245-62. PubMed ID: 19967412
[TBL] [Abstract][Full Text] [Related]
4. Lamin Dysfunction Mediates Neurodegeneration in Tauopathies.
Frost B; Bardai FH; Feany MB
Curr Biol; 2016 Jan; 26(1):129-36. PubMed ID: 26725200
[TBL] [Abstract][Full Text] [Related]
5. Cellular and molecular modifier pathways in tauopathies: the big picture from screening invertebrate models.
Hannan SB; Dräger NM; Rasse TM; Voigt A; Jahn TR
J Neurochem; 2016 Apr; 137(1):12-25. PubMed ID: 26756400
[TBL] [Abstract][Full Text] [Related]
6. Kinesin-1 transport reductions enhance human tau hyperphosphorylation, aggregation and neurodegeneration in animal models of tauopathies.
Falzone TL; Gunawardena S; McCleary D; Reis GF; Goldstein LS
Hum Mol Genet; 2010 Nov; 19(22):4399-408. PubMed ID: 20817925
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of glob1 mitigates human tau mediated neurotoxicity by restricting heterochromatin loss and elevating the autophagic response in drosophila.
Nisha ; Sarkar S
Mol Biol Rep; 2022 Jul; 49(7):6581-6590. PubMed ID: 35633418
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration.
Galán-Ganga M; Rodríguez-Cueto C; Merchán-Rubira J; Hernández F; Ávila J; Posada-Ayala M; Lanciego JL; Luengo E; Lopez MG; Rábano A; Fernández-Ruiz J; Lastres-Becker I
Acta Neuropathol Commun; 2021 May; 9(1):90. PubMed ID: 34001284
[TBL] [Abstract][Full Text] [Related]
9. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders.
Ballatore C; Lee VM; Trojanowski JQ
Nat Rev Neurosci; 2007 Sep; 8(9):663-72. PubMed ID: 17684513
[TBL] [Abstract][Full Text] [Related]
10. Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's disease.
Stozicka Z; Zilka N; Novak P; Kovacech B; Bugos O; Novak M
J Neuroinflammation; 2010 Oct; 7():64. PubMed ID: 20937161
[TBL] [Abstract][Full Text] [Related]
11. Pathogenic tau-induced transposable element-derived dsRNA drives neuroinflammation.
Ochoa E; Ramirez P; Gonzalez E; De Mange J; Ray WJ; Bieniek KF; Frost B
Sci Adv; 2023 Jan; 9(1):eabq5423. PubMed ID: 36608133
[TBL] [Abstract][Full Text] [Related]
12. Tau alteration and neuronal degeneration in tauopathies: mechanisms and models.
Brandt R; Hundelt M; Shahani N
Biochim Biophys Acta; 2005 Jan; 1739(2-3):331-54. PubMed ID: 15615650
[TBL] [Abstract][Full Text] [Related]
13. Neurodegeneration and Alzheimer's disease: the lesson from tauopathies.
Sorrentino G; Bonavita V
Neurol Sci; 2007 Apr; 28(2):63-71. PubMed ID: 17464468
[TBL] [Abstract][Full Text] [Related]
14. Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy.
Kraemer BC; Zhang B; Leverenz JB; Thomas JH; Trojanowski JQ; Schellenberg GD
Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9980-5. PubMed ID: 12872001
[TBL] [Abstract][Full Text] [Related]
15. Targeted Downregulation of
Park SY; Seo J; Chun YS
J Korean Med Sci; 2019 Aug; 34(33):e225. PubMed ID: 31436053
[TBL] [Abstract][Full Text] [Related]
16. Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates.
Vega IE; Cui L; Propst JA; Hutton ML; Lee G; Yen SH
Brain Res Mol Brain Res; 2005 Aug; 138(2):135-44. PubMed ID: 15913839
[TBL] [Abstract][Full Text] [Related]
17. PIWIL1 protein power targets tau therapy.
Soukup SF; Verstreken P
Nat Neurosci; 2014 Mar; 17(3):334-5. PubMed ID: 24569826
[No Abstract] [Full Text] [Related]
18. Combined expression of tau and the Harlequin mouse mutation leads to increased mitochondrial dysfunction, tau pathology and neurodegeneration.
Kulic L; Wollmer MA; Rhein V; Pagani L; Kuehnle K; Cattepoel S; Tracy J; Eckert A; Nitsch RM
Neurobiol Aging; 2011 Oct; 32(10):1827-38. PubMed ID: 19942317
[TBL] [Abstract][Full Text] [Related]
19. Tau phosphorylation and aggregation as a therapeutic target in tauopathies.
Badiola N; Suárez-Calvet M; Lleó A
CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):727-40. PubMed ID: 20942789
[TBL] [Abstract][Full Text] [Related]
20. Axonal degeneration induced by targeted expression of mutant human tau in oligodendrocytes of transgenic mice that model glial tauopathies.
Higuchi M; Zhang B; Forman MS; Yoshiyama Y; Trojanowski JQ; Lee VM
J Neurosci; 2005 Oct; 25(41):9434-43. PubMed ID: 16221853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
